FDA
-
-
-
-
-
-
-
GRAIL closes $110M equity deal with Samsung C&T at $70.05 per share
-
-
-
-
-
-
-
GRAIL to present cancer test data at 2026 ASCO meeting
-
-
-
-
-
-
-
Cancer Is Striking Earlier -- Superpower and GRAIL Are Partnering to Expand Early Detection
-
-
-
-
-
-
-
Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate
-
-
-
-
-
-
-
GRAIL Reports Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Samsung and GRAIL Announce Strategic Collaboration to Bring GRAIL's GalleriĀ® Multi-Cancer Early Detection Test to Asia
-
-
-
-
-
-
-
GRAIL Reports First Quarter 2025 Financial Results
-
331,640 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

